As a leading service provider in the field of antibody discovery and immunotherapy for years, Creative Biolabs has gained rich experience in this area. Now, we are proud to present an advanced platform to provide γδ T cell receptor (TCR) T cell discovery service for therapeutic purpose. This technology enables patients to kill tumor cells and eliminate infected cells with their own T-cells.
T cell therapy is a promising approach for cancer immunotherapy. T cells with modified TCR work in a similar mechanism with CAR-T cell therapy. Both of them function with externally engineered T lymphocytes to wipe out tumors. However, TCR-T cell has an extremely different way of recognizing antigen. TCR-T cell therapy participates in antigen recognition with a natural T-cell receptor leading to the regulation of TCR activity. While CAR-T cell is activated by the antigen and antibody fragment interaction. Another feature of TCR-T cell is that it can recognize the tumor antigen both on cell surface and inside the tumor cells. This means TCR-T cell has more excellent ability to cure solid tumor in clinical.
Features of γδ TCR
There are two different kinds of TCR, αβ TCR, and γδ TCR. The former is widely existed in vivo and can transfer into both helper T cells (Th) and cytotoxic T lymphocyte (CTL). However, its antigen-recognizing ability is closely limited by MHC. To overcome this limitation, we present γδ TCR-T cell discovery service. Although γδ TCR-T cell usually keeps a low percentage in all peripheral blood lymphocyte, it is a vital component of health defense in human. Once the physiological state changes, γδ T cell can relocate and destroy tumor cells effectively without antigen presenting cell initiation or cloning and expansion in lymphoid system. Then it will lead to normal antigen presenting in lymphoid system and in further activate systemic immune response. The foundation of recognizing cancer cells for γδ TCR is figuring out the special-expressed signal molecular on their surface. Creative Biolabs offers a unique strategy to enable γδ TCR express in αβ T cells. Later, tumor-specific proliferation of αβ T cells can be observed and effector CD8+ and helper CD4+ T cells will infiltrate into tumor cells without affecting normal cells.
Fig.1 Strategies to improve the anti-tumor activity of γδ T Cells. (Guranda Chitadze, et al. 2017)
Features of Our Service
Creative Biolabs is in the leading position in the field of immunotherapy with numerous experience. We currently provide professional and advanced service to customers around the world, giving them assistance in time to finish each project successfully. It’s our responsibility to promote your projects and boost the progress to clinical trials with the help of our advanced technologies, platforms, and resources. For more details, please feel free to contact us. We will reply to you as soon as possible.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell as a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE